Abstract
The biological relevance of Fe(II)/Fe(III) is becoming evermore apparent, especially in relation to its potential role in the progression of neurodegenerative diseases such as Parkinson's and Alzheimer's disease. The reported relationship between smoking and a reduced incidence of neurodegenerative disorders prompted this work. In order to investigate whether nicotine can interact with iron, we have studied the electrochemical behaviour of a Fe(II)/Fe(III) redox couple in the presence of nicotine. Solubility issues and lack of available nonreacting salts of nicotine necessitated studies being conducted at low pH values. Cyclic voltammetry experiments revealed a definite alteration in the electrochemical behaviour of the Fe(II)/Fe(III) redox couple suggesting the capability of nicotine to complex with free iron and, hence, reduce its reactivity. This is evident from a slower rate of heterogeneous electron transfer, ks, and a shift from reversible to quasi-reversible behaviour, as characterised from the diffusion coefficient (D), the full width half maximum (FWHM), DeltaEp and Ef. Additional complexation titrations, pH ranging from 1 to 7, confirm a weak complexation reaction occurring between Fe(III) and nicotine.
References
Jan 1, 1992·Free Radical Biology & Medicine·A V KozlovO A Azizova
Jan 1, 1992·Annals of Neurology·D T DexterC D Marsden
Apr 1, 1992·Brain Research Bulletin·G J SengstockG W Arendash
Sep 26, 1997·Drugs & Aging·P A NewhouseE D Levin
Jun 25, 1999·Biochimica Et Biophysica Acta·W LinertG W Arendash
Feb 3, 2000·Mechanisms of Ageing and Development·M Naoi, W Maruyama
Jun 1, 2000·Journal of Inorganic Biochemistry·W Linert, G N Jameson
Mar 7, 2001·Biological Psychiatry·P A NewhouseJ Corwin
Mar 10, 2001·Life Sciences·N Hauptmann, J C Shih
Oct 13, 2001·Bioorganic & Medicinal Chemistry·M FerraliA Pietrangelo
Oct 16, 2001·Drugs & Aging·B Halliwell
May 15, 2002·European Journal of Pharmacology·Hans RommelspacherCharlotte Kloft
Sep 3, 2002·Annals of Neurology·Miguel A HernánJuan J Gestal-Otero
Sep 6, 2002·Neuroscience Letters·Toshio ObataHiroyasu Kinemuchi
Oct 16, 2002·Life Sciences·Mary B NewmanPaul R Sanberg
Jan 16, 2003·Life Sciences·Deepa S MaharajSanty Daya
Feb 5, 2003·Neurotoxicology·Joanna S FowlerNora D Volkow
Mar 7, 2003·Journal of Inorganic Biochemistry·Briar A Colwell, Daniel L Morris
Apr 2, 2003·Neuropharmacology·A CormierG Lagrue
Citations
Jul 8, 2009·International Journal of Molecular Sciences·Yahya E ChoonaraSibongile R Sibambo
Jun 7, 2006·Journal of Microencapsulation·Neha SinghMichael P Danckwerts
Jan 26, 2010·Expert Opinion on Drug Delivery·Ndidi NgwulukaDinesh Naidoo
Oct 1, 2008·Journal of Pharmaceutical Sciences·Yahya E ChoonaraLisa C du Toit
Aug 5, 2008·Neurobiology of Disease·Shannon L Rhodes, Beate Ritz
Jan 9, 2008·Neuroscience and Biobehavioral Reviews·Concepcion Conejero-GoldbergLuis Ulloa
Mar 23, 2007·European Journal of Pharmacology·Dariusz PogockiElzbieta Wałajtys-Rode
Oct 17, 2015·Biopolymers·Lihui XuPing Zhou
Sep 10, 2014·Environmental Research·Marcin DelijewskiEwa Buszman
Aug 14, 2012·Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry·Yijun WangRichard G Compton
Feb 25, 2018·Scientific Reports·Jelena KoraćIvan Spasojević
Jun 15, 2019·Journal of Bioenergetics and Biomembranes·Dominika MalińskaJoanna Szczepanowska
Jul 15, 2018·Neurotoxicity Research·Camila MouhapeGiselle Prunell
Apr 30, 2021·The Analyst·Ashish KumarRajiv Prakash
Apr 26, 2021·Journal of Proteomics·José Navarrete-PereaJoao A Paulo
Aug 3, 2021·ACS Omega·Mathato P MotaungWei Lei